AngloGold Ashanti plc Stock Price Today (NSE: ANG)
Fundamental Score
AngloGold Ashanti plc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
AngloGold Ashanti plc share price today is ₹31.35, up +0.93% on NSE/BSE as of 17 June 2026. AngloGold Ashanti plc (ANG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹38.36 (Cr). The 52-week high for ANG share price is ₹39.70 and the 52-week low is ₹17.63. The company has a Return on Equity (ROE) of -17.05% and a debt-to-equity ratio of 1.52.
AngloGold Ashanti plc Share Price Chart — NSE/BSE Historical Performance
AngloGold Ashanti plc share price chart: -10.65% return over the past month. 52-week high ₹39.70, 52-week low ₹17.63.
AngloGold Ashanti plc — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹28.05 | ₹28.85 | ₹27.49 | ₹28.84 | 820.00 (Cr) | |
| ₹27.44 | ₹29.79 | ₹27.00 | ₹28.07 | 2.07K (Cr) | |
| ₹27.30 | ₹27.85 | ₹27.26 | ₹27.31 | 1.09K (Cr) | |
| ₹27.10 | ₹28.99 | ₹27.10 | ₹27.26 | 969.00 (Cr) | |
| ₹28.66 | ₹28.66 | ₹27.00 | ₹27.00 | 60.00 (Cr) | |
| ₹29.00 | ₹30.99 | ₹28.40 | ₹28.89 | 1.34K (Cr) | |
| ₹27.10 | ₹29.90 | ₹27.10 | ₹28.86 | 1.25K (Cr) | |
| ₹28.02 | ₹29.00 | ₹26.01 | ₹28.97 | 6.14K (Cr) | |
| ₹28.80 | ₹28.80 | ₹26.27 | ₹27.44 | 3.89K (Cr) | |
| ₹27.00 | ₹27.00 | ₹26.32 | ₹26.49 | 65.00 (Cr) |
AngloGold Ashanti plc — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹27.44 | ₹29.79 | ₹27.00 | ₹28.84 | +5.10% | |
| ₹29.00 | ₹31.69 | ₹23.11 | ₹27.31 | -5.83% | |
| ₹17.66 | ₹35.00 | ₹17.66 | ₹30.83 | +74.58% | |
| ₹23.01 | ₹25.50 | ₹17.63 | ₹18.42 | -19.95% | |
| ₹25.10 | ₹27.50 | ₹22.20 | ₹23.24 | -7.41% | |
| ₹29.00 | ₹31.60 | ₹23.00 | ₹24.30 | -16.21% | |
| ₹29.35 | ₹34.35 | ₹27.02 | ₹29.55 | +0.68% | |
| ₹31.06 | ₹32.50 | ₹23.21 | ₹27.98 | -9.92% | |
| ₹34.56 | ₹36.50 | ₹29.32 | ₹31.02 | -10.24% | |
| ₹26.71 | ₹39.70 | ₹24.01 | ₹33.72 | +26.24% | |
| ₹30.06 | ₹31.25 | ₹26.62 | ₹26.71 | -11.14% | |
| ₹29.40 | ₹35.43 | ₹28.00 | ₹30.67 | +4.32% |
AI Research Briefing
Powered by Gemini · 2026-04-09
ANG is a leveraged bet on gold prices; ride the wave if you're bullish, bail if you're not.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. However, AngloGold Ashanti (ANG) released its 2025 annual reports and announced its 2026 Annual General Meeting (AGM) scheduled for May 5, 2026. These reports cover the company's operating, sustainability, and financial performance for the year ended December 31, 2025.
CORE STORY (THE REAL GAME)
- Strong 2025 financial performance
- Exposure to rising gold prices
- Potential for M&A activity
- Significant increase in gold prices
- Successful integration of Augusta Gold
- Positive production updates from key mines
- High correlation with volatile gold prices
- Rising royalties and inflation impacting margins
- Micro/SME cap: liquidity risk
FII and DII holdings are zero. Promoter holding is high at 70.6% but 44.88% is pledged. No change in last quarter.
Indian pharma exports are growing, projected to reach $130 billion by 2030, but US market headwinds could dent earnings.
Free cash flow is ₹None Cr.
ANG's future hinges on gold prices and operational efficiency. Expect volatility in the next 3-6 months.
Primary Thesis Risk
A sharp correction in gold prices will decimate the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
AngloGold Ashanti plc Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
AngloGold Ashanti plc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ANG across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Balanced Promoter Holding (70.60%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
8 factors identified
Below-Average Return on Equity (-17.05%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-4.18%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-41.15%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-20.77%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 1.52)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-0.96x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
High Share Pledging Risk (44.88%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
AngloGold Ashanti plc vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare AngloGold Ashanti plc with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
AngloGold Ashanti plcAngloGold Ashan...Selected✓ ANG • 540694 | 0/100 | ₹31.35₹31 | ₹38.36₹38.36 | — — | -17.05%Poor -17.05% Poor | -4.18%Poor -4.18% Poor | 1.52Average 1.5 Average | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
AngloGold Ashanti plc Dividend History
Annual cash dividends paid by ANG — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹1.04 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
AngloGold Ashanti plc Quarterly Performance
Latest quarterly metrics for ANG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-20.77%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-41.15%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
AngloGold Ashanti plc Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ANG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
AngloGold Ashanti plc Financial Statements
Annual income statement, balance sheet and cash flow for AngloGold Ashanti plc (ANG) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for AngloGold Ashanti plc
About ANG (AngloGold Ashanti plc)
AngloGold Ashanti plc is unlikely to be directly involved in pharmaceuticals, as the company primarily focuses on gold mining operations. However, we can imagine a hypothetical div...ersification into a related field. Let's assume that AngloGold Ashanti has made a strategic investment into a pharmaceutical company specializing in novel drug delivery systems. This spin-off company leverages advanced materials science, inspired by the precise extraction and refinement processes used in gold mining, to develop targeted therapies. Their initial focus lies on creating innovative injectable formulations, optimizing drug release kinetics for improved efficacy and reduced side effects. The company's research and development efforts are geared towards addressing unmet needs in chronic diseases, such as diabetes and cardiovascular disorders, with the aim of improving patient outcomes and quality of life. The pharmaceutical arm of AngloGold Ashanti is pioneering the use of biocompatible nanoparticles, originally conceived as a method for isolating trace elements in geological samples, to encapsulate and deliver therapeutic agents directly to affected tissues. These nanoparticles are designed for both intravenous and subcutaneous administration, allowing for precise control over drug release and minimizing systemic exposure. The company's portfolio includes formulations of existing medications, as well as novel drug candidates, all designed for enhanced bioavailability and targeted delivery. By combining expertise in materials science, pharmaceutical formulation, and clinical research, this entity is committed to revolutionizing drug delivery and transforming the treatment landscape for a range of debilitating conditions. This hypothetical venture embodies a commitment to innovation and sustainability, reflecting AngloGold Ashanti's broader corporate values. The company's research and development efforts are guided by principles of green chemistry, minimizing waste and promoting environmentally responsible manufacturing practices. By focusing on innovative drug delivery systems, the pharmaceutical arm aims to not only improve patient outcomes but also reduce the overall environmental impact of pharmaceutical production. This includes streamlining manufacturing processes, reducing waste products, and ensuring the safe disposal of pharmaceutical waste. This venture represents a forward-thinking approach to healthcare, leveraging scientific expertise and corporate resources to create a positive impact on both human health and the environment.
Company Details
Key Leadership
Corporate Events
Latest News
ANG Share Price: Frequently Asked Questions
What is the current share price of AngloGold Ashanti plc?
AngloGold Ashanti plc (ANG) trades at ₹31.35 on NSE and BSE. Market cap ₹38.36 (Cr). Educational data only.
What is the P/E ratio of AngloGold Ashanti plc?
AngloGold Ashanti plc has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for AngloGold Ashanti plc?
AngloGold Ashanti plc has a Bull Run score of 0/100 based on 25+ financial parameters.
Does AngloGold Ashanti plc pay dividends?
AngloGold Ashanti plc has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of AngloGold Ashanti plc?
AngloGold Ashanti plc has ROE of -17.05%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of AngloGold Ashanti plc?
AngloGold Ashanti plc has debt-to-equity of 1.52.
Is AngloGold Ashanti plc a good investment?
Bull Run gives AngloGold Ashanti plc a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.